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ARTICLE OPEN
Primary care cohort study in the sequence of diagnosing
chronic respiratory diseases and prescribing inhaled
corticosteroids
Ilja Geraets1, Tjard Schermer1,2, Janwillem W. H. Kocks 3, Reinier Akkermans1,4, Erik Bischoff1 and Lisette van den Bemt 1
To prevent unnecessary use of inhaled corticosteroids (ICS), ICS treatment should only be started when the diagnostic process of
asthma and COPD is completed. Little is known about the chronological order between these diagnoses and the start of ICS. We
performed a retrospective cohort study, based on electronic medical records of 178 Dutch general practices, to explore the
temporal relations between starting continuous use of ICS and receiving a diagnosis of asthma and/or COPD. The database
included information of patients who were registered with a diagnosis of asthma and/or COPD in one of the practices during
January 1, 2012 and December 31, 2013. Two or more successive prescriptions of ICS within 6 months were considered as
continuous ICS treatment. The chronological order of events based on available dates were analysed using descriptive analyses. For
8507 patients with asthma, 4024 patients with COPD, and 801 patients with asthma–COPD overlap (ACO), the order of events could
be analysed. In total, 1857 (14.4%) patients started ICS prior to their diagnosis, 11.5, 20.8, and 10.0% of patients with asthma, COPD,
and ACO, respectively. In 53.4% of the patients, the ﬁrst prescription of ICS was a combination inhaler with a long-acting
bronchodilator. In this real-life primary care cohort, one in seven patients started ICS treatment prior to their diagnosis and
approximately half of the patients started with a combination inhaler. Our ﬁndings suggest that there is relevant room for
improvement in the pharmaceutical management of patients with these chronic respiratory diseases.
npj Primary Care Respiratory Medicine  (2018) 28:37 ; doi:10.1038/s41533-018-0106-6
INTRODUCTION
Asthma and chronic obstructive pulmonary disease (COPD) are
prevalent chronic respiratory diseases in primary health care.1,2
Both diseases are frequently treated with inhaled corticosteroids
(ICS). For several years now, ICS are listed in the top ﬁve of highest
expenditure on medicines in the UK as well as in the Nether-
lands.3,4 In asthma, ICS treatment is the cornerstone of pharma-
cological management as it has beneﬁcial effects on lung
function, number of exacerbations, and quality of life.5 In COPD,
the indication for ICS treatment is limited to patients with severe
to very severe disease and frequent exacerbations, as it may
reduce the number of exacerbations.6,7
In contrast with these indications, approximately half of the
patients with COPD are treated with ICS,8–10 whereas in primary
care only 10–20% of the patients seems to have frequent
exacerbations.11 A recent study showed that even COPD patients
with (very) severe airﬂow obstruction did not have more
exacerbations after their ICS treatment was discontinued12 and
there are indications that only patients with high blood eosinophil
levels seem to beneﬁt from continuation of ICS treatment.13 In
addition, treatment with ICS can cause important side effects, like
increased risks of pneumonia and osteoporosis.6,14
The Dutch asthma guidelines recommend to diagnose patients
before prescribing ICS, because ICS can inﬂuence spirometric
outcomes.5,15 However, in daily practice general practitioners
(GPs) may start ICS at the moment a patient presents with
bronchial complaints, before further diagnostic procedures are
initiated or completed. Consequently, absence of airﬂow reversi-
bility can either be the result of well-controlled asthma or of the
absence of disease.5 Two Canadian studies showed that in one
third of the patients with physician-diagnosed asthma, the
diagnosis could not be objectiﬁed.16,17 Some of the patients
might be labelled incorrectly as having asthma based on a good
self-perceived symptomatic response to ICS and continue its use
without an indication.
Another issue related to ICS treatment is the increasing use of
combination inhalers (i.e. an inhaler that contains ICS plus a long-
acting bronchodilator (LABA)). Approximately 40% of the patients
with asthma and COPD use combination inhalers,8 whereas
asthma guidelines recommend to start ICS treatment with a
separate inhaler. Only when the intended treatment effects are
not achieved, switching to a combination inhaler is indicated.5,15
Little is known about the chronological order between
diagnosing patients with asthma and/or COPD and the start of
ICS in daily practice. Primary aim of the current study was to
explore the chronological order of starting ICS maintenance
treatment and receiving a diagnosis of asthma and/or COPD in
patients managed in general practice. We also examined how
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often GPs choose to prescribe ICS in a combination inhaler when
starting ICS maintenance treatment.
RESULTS
Patient selection and ICS treatment
Table 1 shows characteristics of the study population. Of all
patients with asthma in the database, 9.3% was diagnosed with
COPD as well. Among patients with COPD, 17.2% was also
diagnosed with asthma. About half (50.8%) of the COPD patients
without concomitant asthma received ICS treatment. Veriﬁable
dates of diagnosis could be found in 63.2% and 88.1% of the
patients with asthma and COPD, respectively (Fig. 1). All relevant
dates were available for 13,332 patients. This study population
included 8507 patients who were diagnosed with asthma, 4024
patients diagnosed with COPD, and 801 patients with
asthma–COPD overlap (ACO).
Chronological order of diagnoses and ICS treatment
In total, 1898 (14.2%) patients started ICS treatment before a
diagnosis of asthma and/or COPD had been established. Of the
patients with asthma 11.5% started ICS prior to the diagnosis, in
the patients with COPD this was 20.8%. Of the patients with ACO,
10.0% started ICS prior to both diagnoses. Table 2 shows the
numbers and percentages per subgroup. Moreover, Fig. 2 shows
the use of ICS as monotherapy and in a combination inhaler
before their diagnoses were established.
ICS combination inhaler as ﬁrst prescription
Of all patients who were prescribed ICS for maintenance
treatment, 53.4% started with a combination inhaler (Table 2).
Of the patients with COPD, 14.9% started with a combination
inhaler before the diagnosis COPD was established. The same
applies for 6.0% of patients with asthma and 6.0% of the patients
with ACO.
DISCUSSION
This study was performed to provide insight in the chronological
order of events regarding the start of ICS treatment and a
diagnosis of asthma and/or COPD in primary care patients. The
main ﬁndings of this study are that approximately one out of
seven patients started with ICS prior to a diagnosis and that more
than half of the patients started with a combination inhaler
instead of ICS in a separate inhaler.
The use of ICS among COPD patients in our study was
comparable to percentages reported in the literature about COPD
patients in the Netherlands and UK.8,10 A previous study found
that 10–20% of COPD patients have frequent exacerbations.11 This
may be lower in our study population, since a study based on the
same database found that approximately 6% of the COPD patients
had ≥2 exacerbations per year.18 Since 50.8% of the COPD
patients without comorbid asthma in our study used ICS, there
seems to be a signiﬁcant overprescription.
The use of ICS among patients with asthma in our study (58.6%)
was lower than found in literature (71%).8 This difference is
probably explained by the restriction of continuous ICS use in our
study, while other studies report on the number of patients with at
least one prescription of ICS.8
The prevalence of ACO in our study is relatively low (9.3% and
17.2% of asthma and COPD patients respectively), compared to
the assumed prevalence in literature (12–61%).15,19 However, a
recent study assessed the impact of different ACO deﬁnitions on
its prevalence and found that, when ACO was based on recorded
diagnoses in primary care, like in our study, the prevalence was
comparable (10.3%).20
In contrast with the recommendations in the Dutch COPD and
asthma guidelines for GPs, approximately half of the patients who
started with ICS treatment started with a combination inhaler
instead of ICS alone. In a recent Dutch study, GPs mentioned that
they regularly skip treatment steps, in particular in patients with
severe symptoms. Moreover, GPs mentioned that they prescribe a
combination inhaler when patients have an indication for LABAs,
in order to improve the usability and compliance of ICS.8,21
Strengths and limitations
A particular strength of this study is the use of a database with
almost 70,000 patients with an asthma and/or COPD diagnosis
from a primary care setting. This provides a non-selected, real-life
insight in disease management decisions by GPs in daily practice.
Moreover, in our study we focussed on continuous use of ICS. GPs
may prescribe patients ICS for other reasons than asthma or
COPD, and by looking at continuous use only, we excluded these
prescriptions in our study.22
However, temporal relations could only be established for
patients when all relevant dates of events were available and
veriﬁable. Many patients had to be excluded owing to missing
Table 1. Characteristics of patients in the cohort grouped by patients included in the analyses versus patients not included in the analyses
Asthmaa COPDa
Total cohort
(n= 35,384)
In analyses
(n= 9,308)
Not in analysesb
(n= 26,076)
Total cohort
(n= 19,057)
In analyses
(n= 4,825)
Not in analysesb
(n= 14,232)
Male, n (%) 14,619 (41.3) 3597 (38.6) 11,022 (42.3) 10,072 (52.9) 2405 (49.8) 7667 (53.9)
Asthma, n (%) 3286 (17.2) 801c (16.6) 2485c (17.5)
COPD, n (%) 3286 (9.3) 801 (8.6) 2485 (9.5)
ICS, n (%) 20,737 (58.6) 9308 (100.0) 11,429 (43.8) 10,674 (56.0) 4825 (100.0) 5849 (41.1)
LABA single inhaler, n (%) 4533 (14.2) 1631 (17.5) 2902 (12.8) 4547 (28.2) 1418 (29.4) 3129 (27.7)
LAMA single inhaler, n
(%)
5552 (17.4) 1842 (19.8) 3710 (16.4) 11,952 (74.2) 3573 (74.1) 8379c (74.2)
LAMA/LABA combined
inhaler, n (%)
582 (1.8) 162 (1.7) 420c (1.9) 1298 (8.1) 414 (8.6) 884c (7.8)
COPD chronic obstructive pulmonary disease
aAll patients with a diagnosis including asthma–COPD overlap
bMissing values on use of LABA and/or LAMA of asthma (n= 3393) and COPD (n= 2939) compared between the two subgroups were statistically signiﬁcant (p
< 0.05)
cNo statistical signiﬁcant difference (p > 0.05). All other differences in patient characteristics are signiﬁcant
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dates regarding either their diagnosis or their ﬁrst ICS prescription.
Patients who were excluded for the analysis of the chronological
order of events showed statistically signiﬁcant differences in sex
and prevalence of ACO, although these differences were small.
Therefore, it is likely that we introduced selection bias to our study
by this unavoidable selection of patients with veriﬁable dates.
Moreover, we were unable to compare the age of the patients at
the moment of diagnosis. The study results only applied for adult
ACO asthma-COPD overlap, COPD chronic obstructive pulmonary disease, ICS inhaled 
corticosteroid
Patients diagnosed with asthma in database  
(n=52586) 
Patients diagnosed with COPD in database 
 (n=19057) 
Excluded: 
Age<16 years (n=10234) 
No active asthma  
(n=6968)
Excluded: 
Age<35 years (n=622)
Selected asthma patients 
(n=35384) 
No date of diagnosis: 
unknown (n=12752), 
impossible (n=139), or 
same as start data 
collection (n=124)
Selected COPD patients 
(n=18435) 
No date of diagnosis: 
unknown (n=2136), 
impossible (n=0), or same 
as start data collection 
(n=55) 
Asthma patients with verified date of diagnosis  
(n=22369) 
COPD patients with verified date of diagnosis 
(n=16244) 
Asthma patients 
(n=20486) 
COPD patients 
(n=13627) 
ACO patients 
(n=2913) 
Asthma patients + ICS use 
(n=13398) 
COPD patients + ICS use 
(n=6923) 
ACO patients + ICS use 
(n=2403) 
No ICS maintenance 
treatment (n=6704) 
No ICS maintenance 
treatment (n=510) 
No ICS maintenance 
treatment(n=7088) 
Patients with asthma + ICS use 
for temporal analysis 
(n=8507) 
Patients with COPD + ICS use 
for temporal analysis 
(n=4024) 
Patients with ACO + ICS use 
for temporal analysis  
(n=801) 
No start date of ICS 
(n=2899) 
No start date of ICS  
(n=573)  
Missing date of one of the 
diagnoses (n=1029) 
No start date of ICS 
(n=4891) 
Patients with diagnosis of asthma, COPD, or both in database  
(n=69256) 
Fig. 1 Flowchart of the selection procedure of patients with asthma and COPD in the database of the Department of Primary and Community
Care at the Radboud University Medical Center, Nijmegen, the Netherlands
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asthma patients (≥16 years), and by excluding patients who were
diagnosed with COPD before 35 years, some actual cases of COPD
at a young age could be excluded incorrectly (for example, heavy
smokers, other exposures, or alpha 1 antitrypsin deﬁciency).
We had to rely on the diagnostic codes in the medical record,
which could be wrong. As with other routine care database
studies, other relevant information like lung function and smoking
status—that could justify or refute diagnostic conclusions—was
unavailable and information on health-care utilization (like ICS
prescription) was only available for a limited period. Therefore, we
could not verify diagnoses based on objective lung function
outcome, which is an important limitation. Moreover, a reintro-
duction of ICS in a period of more symptoms could be
misinterpreted as a ﬁrst prescription (if previous prescriptions
were prior to the data collection period). We considered two
courses of ICS within 6 months always as continuous ICS use as
the number of prescribed inhalers was unknown. Therefore, two
short courses of ICS within 6 months could be considered
wrongfully as continuous ICS use. However, we believe that this
problem did not frequently occur as the majority of the
population had more than two prescriptions of ICS (94%). We
also had to rely on data available in the database that may not
always be complete (e.g. respiratory visits and diagnoses will not
always be documented) or accurate. Therefore, it could be that the
patient had used ICS for a longer period in the past and this was
not documented in the current electronic medical record.
Moreover, we did not analyse the exact time elapsed between
the start of ICS treatment and the date of diagnosis. This could be
relevant, as the maximum effect of ICS is achieved after several
weeks and will not hamper diagnostic procedures for asthma in
the ﬁrst period a patient uses ICS.
Implications for practice and research
Approximately one in seven patients used ICS prior to the
diagnosis of asthma and/or COPD. Remarkable is the difference
between asthma and COPD patients, 11.5% of the asthma patients
started ICS treatment prior to the diagnosis, while in patients with
COPD this was 20.8%. One possible explanation is that asthma is
usually diagnosed at a younger age than COPD and GPs might be
more conservative in prescribing medication in younger patients.
Another explanation could be that the ﬁrst presentation of
patients with COPD is often during an exacerbation. In these
patients, a ﬁrst treatment of oral and ICS is started before further
diagnostic procedures are done. In contrast to the NICE guideline,
the Dutch primary care guideline on asthma recommend to start
ICS after the diagnostic process is completed. Since ICS can
suppress the bronchial inﬂammation and reduce reversibility of
airway obstruction, a diagnosis of asthma is hard to objectify once
ICS treatment has been started. This makes it difﬁcult to
distinguish between asthma and healthy airways.23 Our results
show that many patients were labelled with a chronic respiratory
disease after starting ICS treatment. There may be medical reasons
to start ICS before the diagnosis is made; however, in these
patients withdrawal of ICS should be considered. The ﬁndings that
more than half of the COPD patients use ICS without having
comorbid asthma and that one in every two patients started with
a combination inhaler shows that GPs often make different
choices than their COPD and asthma guidelines recommend. To
validate our ﬁndings, further research should include information
about the patients’ medical history and actual diagnostic test
results and should analyse in more depth the exact time between
the start of ICS and the date of diagnoses. Moreover, it would be
interesting to compare outcomes between different settings as
Table 2. Number and percentages of chronological order of events per group of patients with the same diagnosis and the number and percentage
of combination inhalers (i.e. ICS plus long-acting bronchodilator) as ﬁrst prescription in patients with ICS maintenance treatment
Chronological order of events Total Combination inhaler
First eventa Second eventa Third eventa n (%) n (% of total)
Asthma (n= 8,507) Asthma → ICS 7525 (88.5) 3294 (43.8)
ICS → Asthma 982 (11.5) 514 (52.3)
COPD (n= 4,024) COPD → ICS 3188 (79.2) 2232 (70.0)
ICS → COPD 836 (20.8) 598 (71.5)
ACO (n= 801) Asthma → ICS → COPD 131 (16.4) 69 (52.7)
Asthma → COPD → ICS 124 (15.5) 67 (54.0)
COPD → ICS → Asthma 31 (3.9) 17 (54.8)
COPD → Asthma → ICS 59 (7.4) 35 (59.3)
ICS → Asthma → COPD 27 (3.4) 12 (44.4)
ICS → COPD → Asthma 12 (1.5) 7 (58.3)
Asthma/COPD → ICS 376 (46.9) 240 (63.8)
ICS → Asthma/COPD 41 (5.1) 29 (70.7)
Total (n= 13,332) 7114 (53.4)
ACO asthma–COPD overlap, COPD chronic obstructive pulmonary disease, ICS inhaled corticosteroids
aEvent: diagnosis of asthma ('asthma'), or diagnosis of COPD ('COPD'), or diagnosis of asthma and COPD ('asthma/COPD') on the same calendar date, or start of
ICS treatment ('ICS')
Fig. 2 Percentages of patients with asthma, COPD, or ACO who
used ICS before their (asthma) diagnosis and the percentages of
combination inhalers (i.e. ICS plus long-acting bronchodilator) as
ﬁrst prescription
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recommendations on the start of ICS use differ between countries
and guidelines.
This study provides a ﬁrst insight in the order of events
regarding the start of continuous treatment with ICS and receiving
a diagnosis of asthma and COPD in primary care. Our ﬁndings
show that one in seven patients ﬁrst start ICS maintenance
treatment and are labelled with a diagnosis of asthma or COPD
afterwards. Furthermore, in contrast with guideline recommenda-
tions, more than half of the patients were prescribed a
combination inhaler instead of ICS in a separate inhaler, some-
times even before asthma and/or COPD was diagnosed. These
ﬁndings suggest there is relevant room for improvement in the
pharmaceutical management of patients with a chronic respira-
tory disease.
METHODS
Design, setting, and data
We performed a retrospective cohort study based on data extracted
from electronic medical records of 178 general practices in the eastern
part of the Netherlands. In the Netherlands, all inhabitants are listed with
a general practice that keeps an individual electronic medical record of
registered patients. This record holds an overview of all diagnoses that
the patient received, including information on outpatient and hospital
care. Data are prospectively recorded and information on health-care
utilisation is available for the period that the general practice maintains
a medical record for the patient in the practice’s electronic patient
journal system. For the current study, electronic medical record data of
69,256 patients who were registered in the participating practices during
January 1, 2012 and December 31, 2013 and had a diagnosis of asthma
and/or COPD were de-identiﬁed and extracted from the practices by the
department of Primary and Community Care at the Radboud University
Medical Center. For each patient, the following data were extracted: year
of birth, sex, medical diagnoses based on International Classiﬁcation of
Primary Care (ICPC) coding, all contacts with the general practice, and all
prescribed medication based on the Anatomical Therapeutic Chemical
classiﬁcation system.24,25 For our study, medical record and prescription
data were available until March 1, 2017 or until a patient left the general
practice or died. The recorded date of diagnosis was not always available
in the data set. In that case, a patient was excluded for the analysis on
chronological order of diagnoses and the start of ICS treatment. For this
study, we used a database that contained only de-identiﬁed, anonymous
information. Therefore, approval of an ethics committee was not
required.
Study population
Asthma patients were selected when they had an ICPC code R96(.01/02)
before 2014 and were at least 16 years in 2014. To exclude patients who
got the diagnosis asthma based on an incidental episode of respiratory
complaints, we only included patients with at least one asthma-related
contact or prescription for asthma medication in the previous 5 years (see
Supplementary Information). We deﬁned an asthma-related contact as a
contact with the GP for dyspnoea (R02), wheezing (R03), and coughing
(R05) based on ICPC code or a plain text notation in a recorded episode of
asthma (R96). A diagnosis of COPD was deﬁned as having received an ICPC
code R95 before 2014 and after the age of 35 years.
ICS and LABAs
All prescriptions of inhalation drugs that contain a corticosteroid (see
Supplementary Information) were taken into account, including separate
inhalers and combined ICS plus LABA inhalers. To exclude incidental ICS
use, only two or more successive prescriptions of ICS within 6 months were
considered as continuous ICS treatment. We categorized the choice of
initial ICS treatment in combination inhalers and ICS in separate inhalers
based on the ﬁrst prescription. The use of separate LABA, long-acting
muscarinic antagonist (LAMA) or combined inhalers (LABA/LAMA) was
described.
Sequence of diagnoses and start of ICS treatment
The chronological order of the start of ICS treatment and a diagnosis of
asthma and/or COPD could be established if a known and veriﬁable date of
the asthma diagnosis, the COPD diagnosis (or, when applicable, both these
diagnoses), as well as a known date of the ﬁrst ICS prescription were
available. Reasons for missing veriﬁable dates of diagnosis were: no date
recorded in the medical record, the recorded date of diagnosis was prior or
equal to the date of birth, or the date of diagnosis was the same as the
starting date of the patient’s electronic medical record. Medication
prescription information was only available for the period that a patient’s
electronic medical record was kept in the practice. In the Netherlands, ICS
is usually prescribed for a period of 12 weeks, therefore we could not be
sure that an ICS prescription in the ﬁrst 14 weeks of medical record
registration of a patient was the ﬁrst prescription or a reﬁll. We therefore
excluded patients with a ﬁrst recorded ICS prescription in the ﬁrst
14 weeks, except when the respiratory diagnosis was clearly subsequent to
the ﬁrst ICS prescription. When the diagnosis of asthma and/or COPD was
recorded on the same day as the ﬁrst ICS prescription, we assumed that
the treatment was started after the diagnosis.
Statistical analysis
Analyses were performed with SPSS version 22.0. Patient characteristics
were analysed using descriptive analyses and differences between
subgroups using Chi-square tests. First, we described the number and
percentages of patients with COPD, asthma, or ACO who used ICS and the
proportion who used a combination inhaler. Next, the chronological order
of asthma and/or COPD diagnoses and the ﬁrst ICS prescription were
analysed. Statistical signiﬁcance was deﬁned as p < 0.05.
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